⌘K
Loading ticker…
BioMarin Pharmaceuticals Inc · Healthcare · Pharmaceutical Products
As of 2026-06-26, BioMarin Pharmaceuticals Inc (BMRN) has a 3-month relative strength percentile of 52 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 50. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 3.1%, relative volume 1.59×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
52 is not yet a leadership-grade RS read, Market Stance is 47
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
BMRN is in a stage 1 base, week 3. Currently in a 87-day base; basing ADR 3.1% (broad 3.0%). VCP detected: inconclusive. RS line below base-start high. Distance from 50d / 200d: 8.4% / 6.0%.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Related searches
BMRN is held by 13 ETFs as of Mar 2026. Top owner: IJH at 0.34% weight, $359M notional. Top 3 carry $956M.
Top 10 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| IJHiShares Core S&P Mid-Cap ETF | 0.34% | $359M |
| VTIVanguard Total Stock Market ETF | 0.02% | $346M |
| VBVanguard Small Cap ETF | 0.15% | $251M |
| VBKVanguard Small-Cap Growth ETF | 0.36% | $140M |
| VXFVanguard Extended Market ETF | 0.15% | $121M |
| MDYState Street SPDR S&P MIDCAP 400 ETF Trust | 0.34% | $82M |
| XBIState Street SPDR S&P Biotech ETF | 1.07% | $79M |
| IWRiShares Russell Midcap ETF | 0.09% | $41M |
| IWDiShares Russell 1000 Value ETF | 0.04% | $25M |
| ITOTiShares Core S&P Total U.S. Stock Market ETF | 0.02% | $14M |
Showing 10 of 13 ETF owners.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | BMRN Jan avg: -1.42% median: -4.23% win: 25% σ: 8.85% n: 4 2022-04-12 → 2026-05-29 | BMRN Feb avg: 1.45% median: 3.57% win: 50% σ: 11.81% n: 4 2022-04-12 → 2026-05-29 | BMRN Mar avg: -2.57% median: -1.51% win: 25% σ: 4.21% n: 4 2022-04-12 → 2026-05-29 | BMRN Apr avg: -5.11% median: -4.57% win: 0% σ: 3.61% n: 5 2022-04-12 → 2026-05-29 | BMRN May avg: -5.34% median: -7.65% win: 20% σ: 6.56% n: 5 2022-04-12 → 2026-05-29 | BMRN Jun avg: 3.58% median: 4.69% win: 50% σ: 7.68% n: 4 2022-04-12 → 2026-05-29 (current) | BMRN Jul avg: 3.24% median: 3.13% win: 100% σ: 1.66% n: 4 2022-04-12 → 2026-05-29 | BMRN Aug avg: 4.12% median: 3.79% win: 100% σ: 3.06% n: 4 2022-04-12 → 2026-05-29 | BMRN Sep avg: -9.53% median: -6.01% win: 0% σ: 9.07% n: 4 2022-04-12 → 2026-05-29 | BMRN Oct avg: -3.28% median: -3.67% win: 25% σ: 4.67% n: 4 2022-04-12 → 2026-05-29 | BMRN Nov avg: 8.25% median: 8.11% win: 100% σ: 7.33% n: 4 2022-04-12 → 2026-05-29 | BMRN Dec avg: 3.54% median: 4.17% win: 75% σ: 3.15% n: 4 2022-04-12 → 2026-05-29 |